Rhomboid domain containing 2 (RHBDD2): A novel cancer-related gene over-expressed in breast cancer

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloCentro de Investigaciones Inmunológicas Básicas y Aplicadas es
cic.versioninfo:eu-repo/semantics/submittedVersiones
dc.date.accessioned2017-09-20T17:01:50Z
dc.date.available2017-09-20T17:01:50Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/6172
dc.titleRhomboid domain containing 2 (RHBDD2): A novel cancer-related gene over-expressed in breast canceren
dc.typeArtículoes
dcterms.abstractIn the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease. In this study, we identified RHBDD2 mRNA and protein expression significantly elevated in breast carcinomas compared with normal breast samples as analyzed by SAGE (n=46) and immunohistochemistry (n=213). Interestingly, specimens displaying RHBDD2 over-expression were predominantly advanced stage III breast carcinomas (p=0.001). Western-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines. We further investigated the occurrence and frequency of gene amplification and over-expression affecting RHBDD2 in 131 breast samples. RHBDD2 gene amplification was detected in 21% of 98 invasive breast carcinomas analyzed. However, no RHBDD2 amplification was detected in normal breast tissues (n=17) or breast benign lesions (n=16) (p=0.014). Interestingly, siRNA mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p=0.001). In addition, analysis of publicly available gene expression data showed a strong association between high RHBDD2 expression and decreased overall survival (p=0.0023), relapsefree survival (p= 0.0013), and metastasis-free interval (p=0.006) in patients with primary ERnegative breast carcinomas. In conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.en
dcterms.creator.authorAbba, Martín Carloses
dcterms.creator.authorLacunza, Ezequieles
dcterms.creator.authorNunez, M. I.es
dcterms.creator.authorColussi, Andrea G.es
dcterms.creator.authorIsla Larrain, Marina Teresitaes
dcterms.creator.authorSegal Eiras, Amadaes
dcterms.creator.authorCroce, María Virginiaes
dcterms.creator.authorAldaz, C. Marceloes
dcterms.extentp. 988–997es
dcterms.identifier.otherDOI:10.1016/j.bbadis.2009.07.006es
dcterms.identifier.urlRecurso completoes
dcterms.isPartOf.issuevol. 1792, no. 10es
dcterms.isPartOf.seriesBiochimica et Biophysica Acta - Molecular Basis of Diseasees
dcterms.issued2009-10
dcterms.languageIngléses
dcterms.licenseAttribution-ShareAlike 4.0 International (BY-SA 4.0)es
dcterms.subjectRHBDD2en
dcterms.subjectgene expression profileen
dcterms.subjectgene amplificationen
dcterms.subjectbreast canceren
dcterms.subject.materiaCiencias Médicases

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Rhomboid domain.pdf-PDFA.pdf
Tamaño:
3.14 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo